Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
about
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesUpdate on the treatment of type 2 diabetes mellitusInitiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix RegimensLiraglutide for treating type 1 diabetes.Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.Challenges and recent advances in the subcutaneous delivery of insulin.A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.Investigational glucagon-like peptide-1 agonists for the treatment of obesity.A Plethora of GLP-1 Agonists: Decisions About What to Use and When.Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.The safety of albiglutide for the treatment of type 2 diabetes.Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.Albiglutide-induced pancreatitis.The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism.Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.Effect of Once Weekly Dulaglutide by Baseline Beta-cell Function in People with Type 2 Diabetes in the AWARD Programme.Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: A Randomized, Double-blind, Placebo-Controlled Trial.Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens.12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitusComparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy
P2860
Q26750510-A0B75FF5-0EBC-4580-B466-6878292E3401Q28067465-9070B816-B1D6-4074-B1F5-6FCB80D4D25BQ28073342-7624D219-E7F7-4AD8-A6D3-06AEAEFA9CECQ28077688-F6C5FFC7-7C91-4E73-AA22-49E927F23684Q35939660-BCAA590F-912E-4CED-9D06-6A04342811A4Q37737456-DB151FF7-A4DD-4A98-AC3C-06F61707969AQ37737463-9914C0F5-3F03-4BF2-A5D2-9153E3F6AD76Q38375731-6E013194-705D-4CFB-BF4E-1E2625B701D6Q38821406-D06DBA61-86C1-4A72-9FE9-2A2E9752F29DQ38910367-FE9F2867-9592-4194-9024-E213F28835B6Q38937735-B83854E7-2491-4F86-95E4-30235DC04931Q38987110-19EB8F57-90F4-4396-9FA6-C8DADC30E74DQ39003218-F6DBA1FA-B2F3-4A84-860D-B4B9588F9595Q39031158-71BD385A-46C5-4A42-BEB4-0337C1D47EB2Q39140474-2DF927C6-4B4F-469F-A407-B95D9E722F96Q39204459-CDD30729-80D0-42B0-A1EC-6D85073716EFQ39415439-AC787857-93CB-42B9-93DC-97A124894749Q40998901-99151AF6-0434-4161-9BD2-279A0077B73AQ42365383-99C9F246-B8F2-45F6-8D2F-8529C8173B9BQ46250756-5C2F81E4-ED5F-44B2-B3BF-BEAFF4991DA0Q47154668-4F69CB80-D9FB-4493-B863-D1B602ABAD73Q47726421-A221DC11-AA21-4608-A9D7-C455CD09F5EEQ47785459-3140E740-A9C1-4808-890B-78388B09BDD6Q48178209-36AF4D95-51F9-427D-8B7B-A501CED483D2Q51243746-950633AC-E97A-4A48-808D-BCC6F96EB846Q51732619-647BD686-31E2-42D4-AFB4-FD24282C3AAEQ51769082-6D84525A-3398-44E5-8D66-E1DCC71360B5Q53482444-256F4F59-68E0-483F-8749-EE05BD359729Q57816534-24605B24-F2B0-4AB0-8A62-B05C92375743Q58167053-B0DB1685-AF84-4356-BE2B-CD3666899366
P2860
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@en
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@nl
type
label
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@en
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@nl
prefLabel
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@en
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@nl
P2860
P921
P356
P1476
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
@en
P2860
P304
P356
10.1111/DOM.12596
P50
P5008
P577
2015-10-29T00:00:00Z
2016-04-01T00:00:00Z